Search Results - "Shapina, M V"

Vedolizumab in patients with inflammatory bowel diseases of in real clinical practice by Shapina, M. V., Nanaeva, B. A.

“…Vedolizumab is currently the only selective biological drug for the treatment of inflammatory bowel diseases (IBD). Its effectiveness and safety has been shown…”
Get full text

Adalimumab and azathioprine in the prevention of postoperative crohn’s disease recurrence by Poletova, A. V., Shapina, M. V.

“…Introduction . Despite improvements in earlier diagnosis and the development of conservative therapy for Crohn’s disease (CD), approximately 70%–80% of…”
Get full text

USE OF 5-AMINOSALICYLIC ACID FOR TREATMENT OF ULCERATIVE COLITIS IN DIFFERENT DOSAGE MODES by M. V. Shapina, I. L. Khalif

“…Preparations of 5-ASA are the first line treatment of ulcerative colitis (UC). Today, in the market of drugs 5-ASA available for the treatment of UC, there are…”
Get full text

Skin diseases and inflammatory bowel diseases. Literature review by Alexandrov, T. L., Khalif, I. L., Khalif, A. Yu, Khismatullina, Z. R., Shapina, M. V.

“…The article presents data of some skin diseases, that often appear in inflammatory bowel diseases (IBD).Some of the skin diseases are directly connected with…”
Get full text

Early administration of genetically engineered biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An experts’ opinion by Abdulganieva, D. I., Bakulev, A. L., Belousova, E. A., Veselov, A. V., Korotaeva, T. V., Lila, A. M., Loginova, E. Yu, Sokolovskiy, E. V., Khobeysh, M. M., Shapina, M. V., Shchukina, O. B.

“…Psoriasis (Ps), psoriatic arthritis (PsA), and inflammatory bowel diseases (IBDs) are characterized by a  progressive course and commonly result in disability…”
Get full text

Early prescription of biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An expert’s opinion by Abdulganieva, D. I., Bakulev, A. L., Belousova, E. A., Veselov, A. V., Korotaeva, T. V., Lila, A. M., Loginova, E. Yu, Sokolovskiy, E. V., Khobeish, M. M., Shapina, M. V., Shchukina, O. B.

“…Psoriasis (Ps), psoriatic arthritis (PsA), and inflammatory bowel diseases (IBDs) are characterized by a progressive course and frequently lead to disability;…”
Get full text

Diagnosis and Treatment of Irritable Bowel Syndrome: Clinical Recommendations of the Russian Gastroenterological Association and Association of Coloproctologists of Russia by Ivashkin, V. T., Maev, I. V., Shelygin, Yu. A., Baranskaya, E. K., Belous, S. S., Belousova, E. A., Beniashvili, A. G., Vasilyev, S. V., Veselov, A. V., Grigoryev, E. G., Kostenko, N. V., Kashnikov, V. N., Kulikovskiy, V. F., Loranskaya, I. D., Lyashenko, O. S., Poluektova, E. A., Rumyantsev, V. G., Timerbulatov, V. M., Fomenko, O. Yu, Khubezov, D. A., Chashkova, E. Yu, Chibisov, G. I., Shapina, M. V., Sheptulin, A. A., Shifrin, O. S., Trukhmanov, A. S., Alekseeva, O. P., Alekseenko, S. A., Baranovsky, A. Yu, Zolnikova, O. Yu, Korochanskaya, N. V., Mammayev, S. N., Khlynov, I. B., Tsukanov, V. V.

“…Aim . Current clinical recommendations accentuate current methods for the diagnosis and treatment of irritable bowel syndrome (IBS). Key points. IBS is a…”
Get full text

CANCERPREVENTIVE IN ULCERATIVE COLITIS by Podolskaya, D V, Shapina, M V, Khalif, I L

“…Colorectal cancer (CRC) is an actual problem today And it occurs 6 times more frequently in patients with inflammatory bowel diseases (IBD) than in healthy…”
Get more information

Colonic cytokines for severe ulcerative colitis by Konovich, Ye. A., Shirokikh, K. Ye, Khalif, I. L., Shapina, M. V.

“…Aim of investigation. To assess colonic cytokines profile at severe ulcerative colitis (UC). Material and methods. Overall 48 biopsy specimens of colonic…”
Get full text

Long-term efficacy and survival of ustekinumab therapy in patients with inflammatory bowel disease by Shapina, M. V.

“…The article reviews data on the long-term effectiveness and survival of biological therapies for treating inflammatory bowel diseases, such as ulcerative…”
Get full text

Theoretical aspects of prescribing ustekinumab as first-line therapy for Crohn’s disease by Shapina, M. V.

“…The treatment of Crohn’s disease is a complex process in which it is necessary to take into account not only the current condition of the patient and the risks…”
Get full text

Mesalazine in the induction of clinical and endoscopic remission of mild and moderate ulcerative colitis by Shapina, M. V.

“…Introduction. Treatment of ulcerative colitis (UC) is necessary to induce remission and subsequently to maintain it. Given the good tolerability, safety and…”
Get full text

Vedolizumab for inflammatory bowel diseasesI by Igor L. Khalif, M. V. Shapina

“…Aim of review. To present literature data on administration of vedolizumab at inflammatory bowel diseases. Summary. The vedolizumab is anti-α4β7-integrin…”
Get full text

Certolizumab pegol in treatment of Crohn's disease with perianal lesions by I L Khalif, B A Nanaeva, M V Shapina, A V Vardanyan

“…Aim. To assess the effectiveness of conservative treatment of Crohn's disease (CD) with perianal lesions. Materials and methods. The study included 20 patients…”
Get full text

Immunological aspects of determination of an adequate biological treatment sequence for inflammatory bowel diseases: the expert board statement (St. Petersburg, May 22, 2021) by Belousova, E. A., Kozlov, I. G., Abdulganieva, D. I., Alexeeva, O. P., Gubonina, I. V., Lishchinskaya, A. A., Tarasova, L. V., Chashkova, E. Yu, Shapina, M. V., Shifrin, O. S., Shchukina, O. B.

“…On May 22, 2021, the Expert Board met in St. Petersburg to discuss their position on immunological aspects of determination of an adequate biological treatment…”
Get full text

Real world practice of medical treatment for moderate and severe inflammatory bowel diseases in Russian Federation, Republic of Belarus and Republic of Kazakhstan: intermediate results of the INTENT study by Knyazev, O. V., Belousova, E. A., Abdulganieva, D. I., Gubonina, I. V., Kaibullayeva, J. A., Marakhouski, Yu. Kh, Chashkova, E. Yu, Shapina, M. V., Shchukina, O. B., Gegenava, B. B., Oliferuk, N. S.

“…Background: The analysis of data obtained from real world clinical practice of management of patients with inflammatory bowel diseases (IBD) is an effective…”
Get full text

Colonic growth factors (G-CSF, GM-CSF) and chemokines (MCP-1, MIP-1β) in severe ulcerative colitis by Konovich, Ye.A., Shirokikh, K.Ye, Shapina, M.V., Khalif, I.L.

“…Aim of investigation. To determine the content of growth factors (G-CSF, GM-CSF) and chemokines (MCP-1, MIP-1β) in resected colon specimens of patients with…”
Get full text

Certolizumab pegol in treatment of Crohn's disease with perianal lesions by Khalif, I L, Nanaeva, B A, Shapina, M V, Vardanyan, A V

“…To assess the effectiveness of conservative treatment of Crohn's disease (CD) with perianal lesions. The study included 20 patients with CD with perianal…”
Get full text

Immunopathogenesis of inflammatory bowel diseases by Ye. A. Konovich, I. L. Khalif, M. V. Shapina

“…The aim of review. To present analysis of data on immunopathogenesis of inflammatory bowel diseases.Key points. At genetically sensitive animals inflammatory…”
Get full text

Chronic inflammatory bowel diseases: the course and treatment methods in Russian Federation by Khalif, I.L., Shapina, M.V., Golovenko, A.O., Belousova, Ye.A., Chashkova, Ye.Yu, Lakhin, A.V., Knyazev, O.V., Baranovsky, A.Yu, Nikolayeva, N.N., Tkachev, A.V.

“…Aim of investigation. To evaluate the prevalence of clinical manifestations and variants of progression for ulcerative colitis (UC) and Crohn’s disease (CD) in…”
Get full text